Lenvatinib

Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting

Thursday, May 14, 2020 - 1:22am

In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

Key Points: 
  • In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
  • Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer.
  • There is no guarantee that any investigational compounds and investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Eisai to Present Latest Data on LENVIMA® (lenvatinib) at the 2020 Gastrointestinal Cancers Symposium

Tuesday, January 21, 2020 - 10:27pm

WOODCLIFF LAKE, N.J., Jan. 21, 2020 /PRNewswire/ --Eisai announced today the presentation of three abstracts at the 2020 Gastrointestinal Cancers Symposium (#GI20) in San Francisco from January 23-25.

Key Points: 
  • WOODCLIFF LAKE, N.J., Jan. 21, 2020 /PRNewswire/ --Eisai announced today the presentation of three abstracts at the 2020 Gastrointestinal Cancers Symposium (#GI20) in San Francisco from January 23-25.
  • Across clinical trials in 799 patients with DTC, RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of LENVIMA treated patients.
  • Fistula Formation and Gastrointestinal Perforation.Of the 799 patients treated with LENVIMA or LENVIMA + everolimus in DTC, RCC, and HCC, fistula or gastrointestinal perforation occurred in 2%.
  • LENVIMA is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/eisai-to-present-latest-data-on-...

International collaboration among Canadian, U.S. and Australian regulators leads to new options for the treatment of cancer

Friday, December 6, 2019 - 3:28pm

On September 20, 2019, Health Canada authorized a new treatment for women who haveadvanced endometrial cancer through the combined use of Lenvima (lenvatinib) and Keytruda (pembrolizumab).

Key Points: 
  • On September 20, 2019, Health Canada authorized a new treatment for women who haveadvanced endometrial cancer through the combined use of Lenvima (lenvatinib) and Keytruda (pembrolizumab).
  • This was the first review conducted under Project Orbis , an initiative of the U.S.Food and Drug Administration (FDA) Oncology Center of Excellence.
  • Project Orbis brings together regulators from multiple countries to review cancer drugs at the same time so that patients can receive earlier access to needed treatments.
  • Between July and November 2019, Health Canada authorized 20 new drugs and medical devices to treat a range of health issues.

Eisai Announces Data at ASCO 2018 Annual Meeting Showcasing LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy Under Strategic Oncology Collaboration with Merck

Thursday, May 17, 2018 - 1:08pm

In RCC, hypertension was reported in 42% of patients on LENVIMA + everolimus vs 10% with everolimus alone (13% vs 2% grade 3).

Key Points: 
  • In RCC, hypertension was reported in 42% of patients on LENVIMA + everolimus vs 10% with everolimus alone (13% vs 2% grade 3).
  • Withhold dose for grade 3 hypertension despite optimal antihypertensive therapy; resume at reduced dose when controlled at grade 2.
  • In RCC, arterial thromboembolic events were reported in 2% of patients on LENVIMA + everolimus vs 6% with everolimus alone (2% vs 4% grade 3).
  • In March 2018, Eisai and Merck, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib).